市場調查報告書
商品編碼
1541272
2024-2032 年按類型、產品、最終用戶和地區分類的上市後藥物警戒和醫療資訊市場報告Post-marketing Pharmacovigilance and Medical Information Market Report by Type, Product, End User, and Region 2024-2032 |
2023年全球上市後藥物警戒與醫療資訊IMARC Group規模達56億美元。
上市後藥物警戒和醫療資訊是在藥品和醫療器材上市後監測其安全性和有效性的做法。它包括收集、監測和預防新藥物、設備和療法的不良反應。它透過澄清與益處有關的風險並反駁錯誤的指示,幫助保護患者免受不必要的傷害。除此之外,它還可以幫助研究人員確定整個藥物配方週期所需的行動。因此,上市後藥物警戒和醫療資訊在醫療保健行業中發揮重要作用,可評估患者和醫療專業人員之間傳遞的訊息的準確性。研究組織也使用它來規範藥物安全指南。
全球老年人口的不斷成長以及糖尿病、高血壓、失智症、心血管疾病和骨質疏鬆症等各種慢性疾病的發生率不斷上升,是增加藥品消費的關鍵因素之一。此外,生活方式、呼吸道和心血管感染以及神經系統和腫瘤疾病日益頻繁,導致全球藥品銷售量不斷增加。這反過來又創造了積極的市場前景。與此一致的是,藥物不良反應 (ADR) 的發生率不斷上升,加上先進的 ADR 報告工具的採用,正在支持市場的成長。除此之外,醫院、診所、實驗室和醫學研究中心的擴張正在刺激全球對藥物和醫療設備的需求。此外,各國政府正在實施多項措施來改善醫療基礎設施和藥物警戒服務並維護醫療資料庫,這正在加強市場成長。此外,領先的市場參與者正專注於外包藥物警戒業務(PVO)並引入基於雲端的醫療資訊系統,以實現最佳準確性、成本效率、風險緩解、領域、改進的時間表和組織敏捷性,預計這將推動市場發展。
The global post-marketing pharmacovigilance and medical information market size reached US$ 5.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 13.0 Billion by 2032, exhibiting a growth rate (CAGR) of 9.52% during 2024-2032.
Post-marketing pharmacovigilance and medical information is the practice of monitoring the safety and efficacy of drugs and medical devices after their launch. It includes collection, surveillance, and prevention of adverse effects of new medicines, equipment, and therapies. It helps protect patients from unnecessary harm by clarifying risks concerning benefits and refuting false indications. Besides this, it assists researchers in determining required actions throughout the drug formulation cycle. As a result, post-marketing pharmacovigilance and medical information finds a considerable role in the healthcare industry to assess the accuracy of the delivered information between patients and medical professionals. It is also used in research organizations for regulating drug safety guidelines.
The growing global geriatric population and the rising occurrence of various chronic medical disorders, such as diabetes, hypertension, dementia, cardiovascular diseases, and osteoporosis, represent one of the key factors increasing the consumption of medicines. In addition, the increasing frequency of lifestyle, respiratory and cardiovascular infections, and neurological and oncological diseases are resulting in the increasing sales of drugs worldwide. This, in turn, is creating a positive market outlook. In line with this, the rising prevalence of Adverse Drug Reactions (ADRs), coupled with the incorporation of advanced ADR reporting tools, is supporting the market growth. Apart from this, the expansion of hospitals, clinics, laboratories, and medical research centers is catalyzing the demand for medications and medical devices across the globe. Moreover, governments of various countries are implementing several initiatives to improve healthcare infrastructure and pharmacovigilance services and maintain medical databases, which is strengthening the market growth. Furthermore, leading market players are focusing on outsourcing pharmacovigilance operations (PVO) and introducing cloud-based medical information systems for optimal accuracy, cost efficiency, risk mitigation, domain, improved timelines, and organizational agility, which is anticipated to drive the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global post-marketing pharmacovigilance and medical information market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on type, product and end user.
Spontaneous Reporting
Intensified ADR Reporting
Targeted Spontaneous Reporting
Cohort Event Monitoring
EHR Mining
Books
Online Media
Journals
Hospitals
Research Organization
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Accenture Plc., ArisGlobal, Cognizant Technology Solutions Corporation, Ergomed Plc, F. Hoffmann-La Roche Ltd., Icon Plc, Parexel International Corporation, Pharmaceutical Product Development, Inc. and Wipro Ltd.